On we entered into the Aspire Purchase Agreement, which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of of Common Shares over approximately months. During the year ended and pursuant to the terms of the Aspire Purchase Agreement, Aspire Capital purchased Common Shares for gross proceeds of thousand ( thousand net of cash share issue costs) and we also issued Common Shares to Aspire Capital in consideration for entering into the Aspire Purchase Agreement. On a cumulative basis to the Company has raised a total of million gross proceeds under the Aspire Purchase Agreement, the total amount that was available under the Agreement.

 

During the months ended the Company issued common shares under the Aspire Purchase Agreement at an average price of per share for gross and net proceeds of approximately million.

 

 

On Aptose entered into an at-the-market (“ATM”) equity facility with Cowen and Company, LLC, acting as sole agent. Under the terms of the ATM, Aptose was permitted to sell Common Shares having an aggregate offering value of million on NASDAQ. The ATM expired on and as at that date the Company had issued a cumulative million of Common Shares pursuant to this facility.

 

During the months ended the Company issued common shares under the ATM at an average price of per share for gross proceeds of million ( million net of share issue costs). Costs associated with the proceeds included a cash commission as well as legal and accounting fees.

 

 

Loss per common share is calculated using the weighted average number of common shares outstanding and is presented in the table below:

 

(in thousands)			Three months ended March 31, 2018				Three months ended March 31, 2017
Net loss		$	(6,814	)		$	(3,292	)
Weighted-average common shares – basic and diluted			29,042				17,399
Net loss per share – basic and diluted		$	(0.23	)		$	(0.19	)

 

The effect of any potential exercise of the Company’s stock options outstanding during the month periods ended and has been excluded from the calculation of diluted loss per common share as it would be anti-dilutive.